top of page

Nelson Advisors: How does the UK HealthTech, MedTech, Health AI markets compare to the European HealthTech, MedTech, Health AI markets?

Writer: Nelson Advisors
Nelson Advisors
4 minutes ago
12 min read
Nelson Advisors: How does the UK HealthTech, MedTech, Health AI markets compare to the European HealthTech, MedTech, Health AI markets?
Nelson Advisors: How does the UK HealthTech, MedTech, Health AI markets compare to the European HealthTech, MedTech, Health AI markets?

The UK is Europe's largest single market for HealthTech, MedTech and Health AI capital, but most of its 2026 lead comes from one company. Strip out Isomorphic Labs and the UK looks like what it has been for a decade: the biggest country in a continent that still lacks growth capital, quick procurement and public-market exits.


That matters because founders and investors rarely choose between "the UK" and "Europe" as abstractions. They choose where to incorporate, which regulator to approach first, which health system to sell into, and where the next round will come from. On each of those questions the two markets now give different answers.


Our article below compares them across capital, deals, regulation, public funding and sentiment, and ends with a SWOT for each. "Europe" here means the EU plus Switzerland, Norway and Iceland. Figures are for 2026 to mid-November unless stated, and sector definitions vary by data provider, so treat the totals as directional.


Venture capital: the UK leads, but one company is the lead


European HealthTech companies raised about €12bn of equity in 2026 to 17 November, across 384 rounds, according to the Tech.eu Funding Explorer. UK companies took €8.4bn of it, roughly 70%.

Country

2026 HealthTech equity raised

UK

€8.4bn

Sweden

€897m

France

€660m

Switzerland

€532m

Germany

€410m

Spain

€349m


That headline flatters the UK. Isomorphic Labs, the London AI drug-design company spun out of Google DeepMind, raised $2.1bn in May and $5bn in November. Tech.eu books the two rounds at about €6.4bn. Remove them and the UK raised roughly €2.0bn of a €5.6bn European total, or 36% (my arithmetic from Tech.eu's figures).


That share matches the longer-run pattern. Galen Growth put 2025 European digital health funding at $6.2bn, with the UK on $2.11bn, about a third, ahead of Finland, France and Germany.


Two cautions apply. Tech.eu's HealthTech category includes AI drug discovery and biotech, so it is wider than devices and digital health. And concentration is a European habit, not only a British one: Sweden ranks second almost entirely because of Neko Health's $700m Series C.


The quieter story is the weakness of the continent's two largest economies. France and Germany each raised less than Sweden in 2026, and Galen Growth recorded both as down year on year in 2025.


Series A and B: thin on both sides of the Channel


Series A and B are where the two markets look most alike, and most fragile. Tech.eu records €737m of Series A and €2.5bn of Series B HealthTech funding across Europe in 2026. Isomorphic's Series B accounts for about €1.8bn, which leaves roughly €0.7bn at each stage for everyone else (my arithmetic).

Cheque sizes are modest. Series A rounds in 2026 cluster between €10m and €35m: Adaptyv Biosystems (€34m), Biolevate (€30m), Prosper AI (€26m), Engitix and Evaro (€21m each). A Series B of $70m to $100m, such as Vitestro in the Netherlands, Ona Therapeutics in Spain or Tandem Health in Sweden, is big enough to make Tech.eu's top-ten lists.


The investors writing the most cheques are public or quasi-public. By deal count, the busiest HealthTech backers of 2026 are Germany's High-Tech Gründerfonds (13 deals), the European Investment Bank (10), Switzerland's Venture Kick (10) and Innovate UK (8). Private Series B leads are scarce in both markets.

US funds fill the gap. They took part in 62% of late-stage European digital health deals in 2025, triple the 2023 share, on Galen Growth's count.


Each side has a policy answer. The British Business Bank made its largest fund commitment to date, £100m to Apposite Capital's healthcare growth fund, aimed at companies nearing a growth inflection. The EU's Scaleup Europe Fund invests from Series B onward. Both are new, and neither has yet changed the numbers above.


Private equity roll-ups: Europe is cheaper, the UK is deeper


Private equity, not venture, now sets the pace of consolidation. Sponsor buyouts in European healthcare rose 276% to €29.6bn in H1 2025, about 93% of M&A value, on Nelson Advisors' figures.


The buy-and-build arithmetic is the same everywhere: buy a platform at 10–12x EBITDA, add bolt-ons at 5–7x, sell the combined group at 14–16x. Where sponsors do it depends on entry prices. Nelson Advisors' buy-and-build report gives these lower-mid-market ranges:


Region

Entry multiple (EV/EBITDA)

UK

11.0–15.0x

Nordics

10.0–13.5x

Benelux

9.0–13.0x

DACH

6.0–13.0x


The UK is the most expensive region. Its targets often carry venture-era revenue multiples without the EBITDA to match, so sponsors favour cash-generative UK assets in workflow, scheduling and occupational health over clinical platforms. G Square's Mayden is one example: in early 2026 it added the patient-engagement platform Wellola and the NHS AI-scribe firm CLAI, according to Grant Thornton.

On the continent, roll-ups stitch together fragmented national software markets. TA Associates and Luxempart took Germany's Nexus AG private. Main Capital built Oiva Health from Finland's VideoVisit across Finland and Denmark. Axcel assembled Sanviva from four distributors in Denmark, Norway, the Netherlands and Sweden.


The fragmentation that frustrates European founders is exactly what sponsors are paid to fix. These figures come from an M&A adviser, so read them as informed market colour, not audited data.


Mergers and acquisitions: the only exit that works


Trade sales and sponsor deals are the exit route in both markets, because public listings are not. The London Stock Exchange and AIM recorded no technology or healthcare admissions in H1 2026, according to Nelson Advisors. The firm also counts Ottobock's €808m Frankfurt listing in October 2025 as the only sizeable recent European MedTech IPO.


Deal volumes are healthy. Grant Thornton counted 114 UK healthcare and pharma services deals in Q1 2026, up 37% year on year, with PE and VC-backed deals up 43%. Tech.eu logs 24 European HealthTech acquisitions in 2026 with €1.0bn of disclosed value, led by Sweden's Saga Diagnostics (€504m), Germany's Kaia Health (€239m) and France's Gleamer (€230m).


The most telling UK deal of the year is not an outright sale. In October, Stryker agreed to put about $400m of preferred equity into CMR Surgical, with an exclusive option to buy the whole company. Cambridge's surgical-robotics champion gets US distribution and a pre-agreed buyer in one transaction.

Buyers differ by market. UK assets attract cross-border strategics, including continental ones: Sweden's Getinge and AddLife both bought UK device distributors this spring. Continental deals are more often intra-European consolidation.


Pricing has reset in both. Nelson Advisors puts average HealthTech revenue multiples at 4.8x in early 2025, down from 6.5x at the 2023 peak, with profitable companies fetching 10–14x EBITDA.


Regulatory pathways: converging on CE, diverging on AI


The biggest regulatory news of 2026 is that the UK stopped trying to run a fully separate device regime. On 21 October the government confirmed indefinite recognition of CE-marked devices in Great Britain. More than 90% of devices registered there already carry a CE mark.


For founders, an EU certificate is now the default passport to both markets. UKCA survives as a domestic route, which the MHRA wants to reposition for first-in-market products such as AI as a medical device.



UK

EU

Core device route

CE mark recognised indefinitely; UKCA for novel products; draft 2026 regulations expected to apply from June 2027

MDR/IVDR through notified bodies; simplification proposed December 2025, still before Parliament and Council

Reliance on other regulators

Pathway for US, Canadian and Australian approvals planned for mid-2028

No equivalent route today

AI

AI Airlock sandbox funded to 2029; a National Commission advising on AI rules

AI Act applies on top of MDR; high-risk duties for AI devices delayed to August 2028

Paying for digital tools

NICE Rules-Based Pathway from April 2026 extends mandated NHS funding to some devices, diagnostics and digital products

National schemes: Germany's DiGA (50 permanent and 13 provisional apps in September 2026), France's PECAN


Brussels is moving toward simplification, and the Commission estimates savings of about €3.3bn a year. Timing is uncertain: Parliament's rapporteur tabled more than 130 amendments in July. On AI, the May 2026 Digital Omnibus deal kept medical devices under both rulebooks.


The trade-off is clear. The EU offers one certificate for 27 countries, but with crowded notified bodies and two layers of AI law. The UK offers a more flexible regulator and a live sandbox, but a smaller market and no route that avoids either CE or UKCA.


Government funding initiatives: targeted pots versus pooled scale


The UK ties public money to NHS reform; the EU pools it to fix the growth-capital gap. Neither has a HealthTech-specific fund of real size.


In the UK, the Life Sciences Sector Plan of July 2025 commits more than £2bn over the spending review period. It includes £520m for a manufacturing fund and more than £650m for Genomics England, alongside the procurement reforms above: the Rules-Based Pathway and an NHS Innovator Passport. The state also invests directly. The UK Sovereign AI Fund backed both Isomorphic rounds, and the British Business Bank's £100m Apposite commitment targets HealthTech scale-ups.


In the EU, the centrepiece is the Scaleup Europe Fund. It targets €5bn, is managed by EQT, and was legally established on 4 August 2026 with €1bn from the Commission. Six weeks later it led Tandem Health's $100m Series B, its first healthcare deal.


Below that sit older instruments. The European Investment Bank and the EIC Fund did 10 and 6 HealthTech deals respectively in 2026, and national vehicles such as Germany's High-Tech Gründerfonds remain the most active early backers. Reimbursement schemes like DiGA act as demand-side funding that the UK has only begun to match.


The difference is one of design. UK support is concentrated and closely linked to a single buyer. EU support is larger in aggregate, but spread across 27 states and every deep-tech sector.


Nelson Advisors: How does the UK HealthTech, MedTech, Health AI markets compare to the European HealthTech, MedTech, Health AI markets?
Nelson Advisors: How does the UK HealthTech, MedTech, Health AI markets compare to the European HealthTech, MedTech, Health AI markets?

Confidence in local markets: strong in the lab, weak at the till


Both markets are trusted as places to invent and test, and doubted as places to earn revenue.


The UK evidence is the ABHI Pulse of the Sector survey for 2025. More than 40% of companies planned to seek first approvals in the US or EU before the UK. About 60% expected to delay launching innovative products in Great Britain, and 30% had removed products from the UK market. Respondents rated the UK ahead of the US and EU for research, and the US ahead of both for innovation overall. The 2026 survey closed on 30 September and has not yet reported, so the CE decision is not reflected.


Europe's picture is mixed in a different way. It was the fastest-growing digital health region in 2025, up 15% against 7% for North America, on Galen Growth's data. Yet nearly a third of EU unicorns have moved abroad over 15 years in search of capital.


Confidence is highest where payment is codified. Germany's DiGA route generated 423,000 prescriptions and a €152m market in a year: slower than hoped, but predictable. In both markets, the US remains the place companies expect to make their money.


Founders' perspectives: one buyer or twenty-seven


UK founders complain about depth of adoption; European founders complain about breadth.


The UK grievance is the "pilot graveyard". Nelson Advisors describes NHS sales cycles of 6 to more than 24 months for non-mandated digital products, with most validated tools stalling after a hospital trial. A contract with one trust does not carry to the next, which is the problem the Innovator Passport is meant to solve. What founders value is the other side of the same coin: a single health system, strong clinical research, and a regulator willing to run a sandbox.


Continental founders face languages, payers and procurement rules that change at every border. The upside is that a codified route, once cleared, pays. DiGA and PECAN give digital products a defined path to reimbursement, though with attrition: Nelson Advisors estimates about 20% of apps that entered the DiGA directory have since been removed.


The strongest founders treat fragmentation as a moat. Tandem Health holds three separate MDR Class IIa certifications and serves care organisations in 14 European markets. Its chief executive, Lukas Saari, said on announcing the round that "Europe should be setting the standard for how AI enters healthcare".

In practice the playbook is converging. Get the CE mark first, since it now covers Great Britain. Use the NHS for evidence, Germany or France for early reimbursed revenue, and the US for scale.


Investors' perspectives: bigger cheques, fewer bets, no exits


Investors in both markets are concentrating capital and worrying about how to get it back.


Concentration first. Seven rounds of $100m or more made up 56% of European digital health venture investment in H1 2025, on Nelson Advisors' numbers. In 2026 the largest rounds were led from outside the usual European venture base: Greenoaks and Sequoia at Isomorphic, Lightspeed at Neko Health, Stryker at CMR Surgical, and an EU-backed fund at Tandem.


Then liquidity. Nelson Advisors counts 13 European digital health exits with $552m of disclosed value in Q1 2026, and reports LP portfolio sales clearing at 60p to 70p per pound of net asset value. Its argument is that Europe has an exit problem, not a funding problem: funds that cannot return cash cannot raise, and so cannot lead Series B rounds.


Views on the UK divide by investor type. Venture investors like its research base, talent and density of early-stage companies. Buyout investors see high entry prices and weak EBITDA conversion, and often prefer DACH or Benelux software assets at lower multiples.


Both groups agree on one test. A company needs proven reimbursement or contracted recurring revenue in at least one major system before a growth round, wherever it is based.


Success stories: what 2026's winners have in common


The year's standout companies show the UK winning on science-led scale and the continent winning on consumer and clinical AI built for many markets.


Company

Base

2026 milestone

What it shows

UK

$7.1bn across Series B and C

Global capital will come to London for frontier Health AI

UK

About $400m from Stryker, with an option to acquire; more than 45,000 patients treated

UK MedTech can reach global scale, usually with a US partner

Oviva

UK

€200m Series D

Reimbursed digital care in several systems attracts late-stage money

Sweden

$700m Series C at a reported valuation near $7bn

Self-pay prevention can scale outside public procurement

Sweden

$100m Series B led by the Scaleup Europe Fund

Multi-country certification is a defensible position in clinical AI

Kaia Health and Gleamer

Germany, France

Acquired for €239m and €230m

Mid-sized trade sales are the realistic European exit


Three patterns repeat. Each winner solved payment before scaling, whether through reimbursement, self-pay or pharma partnerships. Each raised its largest round from international investors. And each treats its home market as a base, not a destination: Neko is opening in New York, and CMR's deal is built around US distribution.


SWOT analysis


The two markets have mirror-image profiles: the UK is concentrated and capital-rich but dependent on one buyer, while Europe is broad and better reimbursed but fragmented.



UK

Europe

Strengths

Largest national share of European HealthTech capital; deep research and AI talent; single health system for evidence; flexible regulator with an AI sandbox

Larger combined market; codified digital reimbursement in Germany and France; active public co-investors; strong MedTech engineering base

Weaknesses

Slow, fragmented NHS adoption; funding totals skewed by a few rounds; highest PE entry multiples; no local IPO market for the sector

27 sets of payers and procurement rules; slow notified bodies; France and Germany raising less than Sweden; reliance on US late-stage capital

Opportunities

CE recognition removes dual certification; Rules-Based Pathway and Innovator Passport; pension capital through Mansion House reforms; UKCA as a fast route for AI devices

MDR/IVDR simplification; Scaleup Europe Fund at Series B and beyond; European Health Data Space; PE roll-ups creating regional champions

Threats

Companies launching abroad first; US acquirers taking the best assets early; NHS budget pressure; reforms announced but not delivered

Dual AI Act and MDR burden; legislative delay; unicorns relocating; apps delisted from reimbursement schemes


So which market is stronger?


The UK is the stronger place to start and fund a HealthTech, MedTech or Health AI company; continental Europe is increasingly the stronger place to get paid.

The UK's lead in capital is real even after removing Isomorphic Labs, at roughly a third of European funding from one country. Its research base and regulator are advantages no single EU member state matches. Its weakness is turning NHS pilots into contracts, and the 2025 and 2026 reforms have not yet been tested at scale.


Europe's advantages are structural and slower to show. Reimbursement routes exist, a €5bn growth fund has started investing, and regulation is being simplified. Its weaknesses are fragmentation and a legislative calendar nobody controls.


For founders, the October CE decision makes this less of a choice than it was. One certificate now opens both markets, so the sensible plan uses the UK for evidence and early capital and the continent for reimbursed revenue. For investors, the shared constraint matters more than the differences: without a working IPO market, returns in both depend on trade buyers and sponsors.


The figures to watch in 2027 are the UK's share of funding without a mega-round, the first NHS contracts won through the Innovator Passport, and whether the MDR revision passes.


Nelson Advisors > European Healthcare Technology Investment Banking


Nelson Advisors specialise in Mergers and Acquisitions for European HealthTech, MedTech, Digital Health, Healthcare IT, Healthcare AI companies in the Lower to Mid Market ranging from $25M to $250M EV. www.nelsonadvisors.co.uk


Healthcare.Digital is the Google News approved HealthTech and MedTech Thought Leadership platform for Nelson Advisors, positioning them as a specialised authority on European Healthcare Technology M&A and strategic corporate development. https://www.healthcare.digital 


Nelson Advisors publish Europe's Leading Healthcare Technology Investment Banking Newsletter every week, join 5000+ HealthTech and MedTech subscribers today! https://lnkd.in/e5hTp_xb 



Nelson Advisors LLP


Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT




Meet Nelson Advisors @ Events in 2026


Digital Health Rewired > March 2026 > Birmingham, UK  


NHS ConfedExpo  > June 2026 > Manchester, UK 


HLTH Europe > June 2026, Amsterdam, Netherlands


HIMSS AI in Healthcare > July 2026, New York, USA


Bits & Pretzels > September 2026, Munich, Germany  


HealthInvestor Healthcare Summit > September 2026, London, UK 


World Health Summit 2026 > October 2026, Berlin, Germany


HLTH USA 2026 > October 2026, USA


Global Health Exhibition 2026 > October 2026, Riyadh, Saudi Arabia


Web Summit 2026 > November 2026, Lisbon, Portugal  


MEDICA 2026 > November 2026, Düsseldorf, Germany


Leaders in Health Summit 2026 > November 2026, London, UK 


Venture Capital World Summit > December 2026, Toronto, Canada


Meet Nelson Advisors @ Events in 2027


Digital Health Rewired > March 2027 > Birmingham, UK


Barclays Health Elevate > March 2027, London, UK 


NHS ConfedExpo  > June 2027 > Manchester, UK 


HLTH Europe > June 2027, Amsterdam, Netherlands


Nelson Advisors specialise in Mergers and Acquisitions for European HealthTech, MedTech, Digital Health, Healthcare IT, Healthcare AI companies in the Lower to Mid Market ranging from $25M to $250M EV. www.nelsonadvisors.co.uk
Nelson Advisors specialise in Mergers and Acquisitions for European HealthTech, MedTech, Digital Health, Healthcare IT, Healthcare AI companies in the Lower to Mid Market ranging from $25M to $250M EV. www.nelsonadvisors.co.uk


Comments


Commenting on this post isn't available anymore. Contact the site owner for more info.
bottom of page